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ABSTRACT 
The main aim of this review which is published by the European Medicines Agency EMEA and the U.S. Food and Drug Administration (FDA) [1-7] 
is to describe about the importance of protocol in clinical trials. When developing a successful study design and writing a protocol, the 
researcher must address various successful components including the type of data being collected, data handling, record keeping, outcome 
measures. A research protocol is a document that describes the background, rationale, objectives, design, methodology, statistical 
considerations and organization of clinical research project.  
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INTRODUCTION: 
A protocol is the most important quality control tool for all 
aspects of clinical trial.  A protocol can be made better by 
explaining the features of the confirmatory trial clearly 
during its preparation. It describes how clinical trials are 
conducted. 
It acts as a proof in various research trials as well as in 
clinical trials. A protocol can be made better by explaining 
the features of the confirmatory trial clearly during its 
preparation. 
Nature and purpose of a clinical trial: 
This review mainly describes about the protocol which 
shows statistical design and data analysis of a particular 
experiment. Clinical trials are very complex and different 
from protocol. While making a protocol, a clinical trial 
statistician not only should be careful about the design and 
method of the protocol but also the administrative and 
organizational purpose of it. A documented contract is done 
between a sponsor and investigator in the form of a 
protocol. The agencies and individuals which are involved in 
the project are identified by the protocol and the 
responsibilities and obligations are assigned to them. 
All pharmaceutical companies name/number their protocol. 
The various topics in a protocol are: 
 Introduction: It gives information about the article, its 
effect, previous research done and the current topic. 
 Objective: It explains about the medical conjecture. 
 Subject selection criteria: It explains the criteria for 
selecting the subject and safety to study the subject. 
 Study medication: It explains about the treatment for 
test, control, packaging , mechanism for masking the 
treatment. 
 Plan and procedure: It makes a schedule of doses, tests, 
visits which are to be done by the investigative staff, 
various rules for discontinuing subjects, reports of 
adverse events, administration of the medicines given 
in case of emergency. 
 Efficacy and safety end point criteria: It includes the 
safety endpoints of primary and secondary efficacy, 
collected, monitored, quality control data collection 
etc. 
 Data analysis and statistical considerations: It 
describes the primary and secondary analyses, 
variables and statistical design consideration. 
 Committees: It identifies different committee. Eg: 
committee for data monitoring, end point 
classification, steering  and executive committees.[2,4] 
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 Pharmacokinetic/pharmacodynamic investigation: It 
consists of sub protocol which includes population 
pharmacokinetics, exposure-response as secondary 
analyses. 
According to The ICH Section E6 on Good Clinical Practise[1], 
the sponsor should appoint qualified individuals (eg: 
biostaticians, pharmacologists and physicians) who will be 
involved throughout the trial process from designing of the 
protocol to determine the final report of the protocol. 
Content of the statistical section of a protocol for 
clinical trial: 
ICH advices to specify the analysis in advance i.e in order to 
get the result and conclusion of a clinical trial the extent to 
which the procedure is followed should be pre planned. 
Primary Variable(s) and analyses: 
The primary variables which are identified by the protocol 
should be explained why they were chosen[4].After the 
analysis the results which can be predicted are included in 
the protocol[3]. 
From a given trial many number of analysis can be 
conducted. In a protocol the trial data which acts a proof and 
the  data which is obtained after analysis should be 
differentiated. 
Primary statistical objective: 
In this the primary objective of investigation is converted 
into statistical terms. 
Primary analyses: 
These are the statistical data that provide information about 
the primary investigational conjecture. Different analysts 
give different judgments and opinions of what principle 
features should be present in the analysis. Most of the 
analysts determine the statistics upon which the primary 
analysis is based on in a protocol. Hence the principle 
features of analysis should be prespecified in the protocol or 
else due to different opinions it may lead to confusion. 
Decision rules: 
A protocol should design the pattern and different methods 
to combine the data obtained from analysis In order to 
interpret the results very fast. 
It contains information on how a prespecified set of statistics 
is used to evaluate the primary conjecture. It allows the 
experimenters to conclude whether the treatment is 
equivalent. Decision rules about how to conclude the result 
from the arithmetic. 
Error control: 
When a number of hypothesis is to be tested the type of 
errors, the method of controlling, the level to which they are 
controlled should be stated. The method of controlling type I 
errors should be stated. 
Analyses subsets: 
It includes subsets which contain data related to the primary 
analysis. 
Design and number of subjects: 
A statistical design should be set in an experiment. It justifies 
the planned number of subjects. 
Sometimes trials are designed in such a way that it is 
stopped after certain amount of information has been 
gathered. 
Secondary variable(s) and analyses: 
Secondary variables are those measurements which support 
the primary objective or the measurements related to 
secondary objective. 
Interim analyses: 
If a particular clinical trial is to be stopped, extended or 
modified they are based on interim analyses. The criteria for 
taking the decision should be described in the protocol. 
Problem data: 
The ICH E9 document says that the specific procedures 
should be mentioned in the protocol to minimize the 
irregularities which causes impairment in the statistical 
analysis.[7] 
Safe data: 
A safety data summarizes and displays the information. If 
there are any safety issues the sponsor should prespecify 
them. 
CONCLUSION: 
Protocol is a documented proof which clearly specifies about 
the research plan for the clinical trial. It describes about the 
safety and risk benefits during a clinical trial. The 
development of the protocol should be joint effort of 
representatives from several disciplines such as clinical 
pharmacologists, pharmacists, biostaticians, physicians and 
other relevant health care workers as well as experts in 
traditional medicine. 
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